Australia markets closed

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2200-0.0300 (-2.40%)
At close: 04:00PM EST
1.1800 -0.04 (-3.28%)
After hours: 07:41PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.2500
Open1.2400
Bid0.0000 x 800
Ask0.0000 x 1000
Day's range1.2000 - 1.2600
52-week range0.7900 - 4.8900
Volume168,544
Avg. volume215,985
Market cap29.844M
Beta (5Y monthly)0.29
PE ratio (TTM)N/A
EPS (TTM)-1.8930
Earnings date20 Feb 2023 - 24 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.50
  • GlobeNewswire

    EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement

    – Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of the Company, has signed an accounts receivable-backed factoring agreement, to support its operations, with Bay View Funding, a wholly owned subsidiary of Heritag

  • GlobeNewswire

    Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

    – Paula Brown Stafford, President and Chief Executive Officer of Novan to participate in a live moderated panel discussion on Thursday, December 8th at 11:00 AM ET – DURHAM, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a panel discussion titled, “Distraction or Destruction?: What’s New/Next in the Industry,” at the Cantor Fitzgerald Medi

  • GlobeNewswire

    Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    – Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted around the end of 2022 – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the third quarter ended September 30, 2022 and provided a corp